Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.

Austin, TX, USA

Triumvira Immunologics

Alix Ventures

BIOS Community

Leverage our network to build your career.

#### Welcome!

Thank you for joining Bios Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Bios network as they come up.

You can always update this information later.

Welcome to the Bios talent network

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Bios company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Join TechBio Companies Driving Patient Impact